Sloan-Kettering Institute to Use GeneBio’s Phenyx Protein ID Platform
News Aug 14, 2008
Geneva Bioinformatics has announced that the Sloan-Kettering Institute, part of the Memorial Sloan-Kettering Cancer Center, has licensed GeneBio’s PhenyxServer protein identification and characterization software to be used in the laboratory of Paul Tempst, PhD.
Dr. Paul Tempst’s team is one of the five Clinical Proteomic Technology Assessment for Cancer (CPTAC) teams, a collaborative network established by the National Cancer Institute (NCI) whose goal is to enable all researchers conducting cancer-related protein research at different laboratories to effectively use proteomic technologies and methodologies to directly compare and analyze their work.
Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s comprehensive platform for protein identification and characterization, including extensive PTM searches, results quantitation, multiple results comparison, etc.
Phenyx is specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment while offering a flexible user experience and an adaptable architecture to help instil confidence in results assessment.
“We are excited to see how Phenyx matches up with other search engines in the lab and our various projects,” said Paul Tempst, Lab Head of the Protein Center which is a part of the Molecular Biology Research Program at the Sloan-Kettering Institute.
“We are happy to have signed on Dr. Tempst’s group as a Phenyx user,” said Nasri Nahas, CEO of GeneBio. “The Phenyx platform adds great value due to its unique capabilities and level of flexibility; we are excited to provide Paul’s team with the best possible scoring schemes in order for them to truly take advantage of their data within the framework of their Proteomics research studies.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE